Activity of p44/42 MAPK tends to be high in breast cancer [49], and so it is perhaps counterintuitive that RGS2, which suppresses p44/42 MAPK phosphorylation in oxytocin signalling, is highly expressed in breast cancers and cancer cell lines. This evidence concerns the gene RGS2 and breast carcinoma.